Federal Court Blocks Mailing of Mifepristone Abortion Pill

A federal appeals court has restricted access to one of the most common methods of abortion in the United States by blocking the mailing of mifepristone prescriptions. In a unanimous ruling issued on May 1, 2026, a three-judge panel of the New Orleans-based 5th U.S. Circuit Court of Appeals required that the medication be distributed only in person and at clinics.

The decision overrules regulations established by the federal Food and Drug Administration (FDA), specifically suspending a Biden-era regulation that allowed the drug to be prescribed via telehealth and dispensed through the mail. This ruling immediately halts telemedicine abortion pill prescriptions nationwide while further litigation continues.

Legal Challenges and Immediate Impact

The ruling stems from a lawsuit filed by Louisiana Attorney General Liz Murrill, who argued that FDA rules allowing mifepristone to be dispensed by mail undermined Louisiana’s ban on abortions at all stages of pregnancy. Murrill described the court’s decision as a victory for life.

The impact of the ruling extends beyond states with abortion bans, affecting patients in all states regardless of local restrictions. Medical providers have expressed concern over the sudden shift in access. Josh Thorburn, owner of Eddie’s Pharmacy in Los Angeles, stated that the ruling represents a huge access issue for patients that haven’t got providers close by, or providers close by who are willing to prescribe.

On May 2, 2026, two manufacturers of the drug sought emergency intervention from the U.S. Supreme Court to block the appellate court’s decision. Danco Laboratories and GenBioPro, which produces a generic version of mifepristone, both requested a pause on the ruling. Danco Laboratories asserted that the decision injects immediate confusion and upheaval into highly time-sensitive medical decisions.

Medical Context and Clinical Use

Mifepristone was approved in 2000 as a safe and effective means of ending early pregnancies. In clinical practice, This proves typically used in combination with a second medication, misoprostol. While the current ruling does not affect the distribution of misoprostol, that drug is considered less effective when used on its own without mifepristone.

The availability of mifepristone through telehealth has become a central point of contention in reproductive health policy. Data indicates that the majority of abortions in the U.S. Are administered using pills, with approximately one in four of those prescriptions occurring via telehealth.

Some providers suggest that the ability to access these medications through telehealth is a primary reason why the total number of abortions in the U.S. Has not declined since the overturning of Roe v. Wade in 2022.

Broader Implications for Public Health

The ruling marks a significant shift in how federal drug regulations are handled by the courts. Mary Ziegler, a professor at the University of California at Davis School of Law and an expert on abortion law, noted the potential for the ruling to fundamentally change the landscape of healthcare access.

We’re now going to see, I think in a way we haven’t before, what the nation will look like when abortion bans are actually in effect.

Mary Ziegler, Professor at University of California at Davis School of Law

In response to state-level bans, several Democratic-led states have implemented so-called shield laws designed to protect providers who prescribe medications via telehealth and mail them to patients in states where abortion is restricted. These laws are currently being tested through various civil and criminal cases in Texas and Louisiana.

The FDA and the U.S. Department of Justice did not immediately respond to requests for comment following the 5th U.S. Circuit Court of Appeals decision.